All In Biotech

Drug Trial Radar · NCT06432296

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

A Randomized, Controlled, Multi-Center Phase III Clinical Study to Evaluate the Efficacy and Safety of M701 for Intraperitoneal Injection in Patients With Malignant Ascites Caused by Advanced Epithelial Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

312

Actual

Start

Mar 25, 2024

Primary completion

Aug 22, 2025

Study completion Dec 12, 2026

Sponsor

Lead sponsor
Wuhan YZY Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
May 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Controlled, Multi-Center Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody (M701) for Intraperitoneal Injection to Paracentesis alone in Patients with Malignant Ascites Caused by Advanced Epithelial Solid Tumors.

Conditions

  • Malignant Ascites

Interventions

  • M701Drug

    Intra-peritoneal infusion of M701 in experimental group (M701 group\_

  • paracentesisProcedure

    Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PuFSTime frame: Time from the end of drainage of ascites at C1V4 to the start of the next drainage or death (up to 6 months)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Medical Center of Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.